Work

Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM)

Year: 2017

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2017.07.164

Authors: Guenther Koehne, Sean Devlin, Neha Korde, Sham Mailankody, Landau Heather, Hani Hassoun, Alexander Lesokhin, Nikoletta Lendvai, David Chung, Nicholas Sarlis, Sergio Giralt, Ola Landgren

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2751878790

FWCI:

Cites:

Cited by: 1

Related to: 10